What is the recommended dosage and treatment plan for Cotrimixazole (trimethoprim/sulfamethoxazole)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cotrimoxazole (Trimethoprim-Sulfamethoxazole) Dosing and Treatment Guidelines

For most common bacterial infections, cotrimoxazole is dosed as 1 double-strength tablet (800mg/160mg sulfamethoxazole/trimethoprim) twice daily, with duration varying by indication from 3 days for uncomplicated cystitis to 14-21 days for severe infections like Pneumocystis pneumonia. 1, 2, 3

Standard Adult Dosing by Clinical Indication

Urinary Tract Infections

  • Uncomplicated cystitis: 1 double-strength tablet twice daily for 3 days 1
  • Pyelonephritis: 1 double-strength tablet twice daily for 14 days (only when pathogen confirmed susceptible) 1
  • General UTI treatment: 1 double-strength tablet or 2 single-strength tablets (400mg/80mg) every 12 hours for 10-14 days 2, 3

Respiratory Infections

  • Acute exacerbations of chronic bronchitis: 1 double-strength tablet twice daily for 14 days 2, 3
  • Pneumocystis jirovecii pneumonia (treatment): 75-100 mg/kg/day sulfamethoxazole with 15-20 mg/kg/day trimethoprim divided every 6 hours for 14-21 days 4, 1, 2, 3
  • PCP prophylaxis: 1 double-strength tablet daily (preferred) or 1 single-strength tablet daily or 1 double-strength tablet three times weekly 4

Gastrointestinal Infections

  • Shigellosis: Same dosing as UTI (1 double-strength tablet twice daily) but for only 5 days 2, 3
  • Traveler's diarrhea: 1 double-strength tablet twice daily for 5 days 4, 2, 3

Skin and Soft Tissue Infections (Including MRSA)

  • Standard dosing: 1-2 double-strength tablets twice daily for 7-10 days 1

Pediatric Dosing (Children ≥2 Months)

General Infections

  • Standard dose: 40 mg/kg/day sulfamethoxazole with 8 mg/kg/day trimethoprim divided every 12 hours 2, 3
  • UTI and acute otitis media: Same standard dose for 10 days 2, 3
  • Shigellosis: Same standard dose for 5 days 2, 3

Pneumocystis Pneumonia

  • Treatment: 75-100 mg/kg/day sulfamethoxazole with 15-20 mg/kg/day trimethoprim divided every 6 hours for 14-21 days 4, 2, 3
  • Prophylaxis: 750 mg/m²/day sulfamethoxazole with 150 mg/m²/day trimethoprim divided twice daily on 3 consecutive days per week (maximum 1600mg/320mg daily) 2, 3

Prophylactic Dosing

UTI Prevention

  • Daily prophylaxis: 40mg trimethoprim/200mg sulfamethoxazole (half single-strength tablet) once daily 5
  • Alternative regimen: 40mg/200mg three times weekly 5
  • Postcoital prophylaxis: 40mg/200mg or 80mg/400mg (single-strength tablet) once after intercourse 5
  • Critical caveat: Only use when local E. coli resistance rates are <20% 5

PCP Prophylaxis in HIV/Immunocompromised

  • Adults: 1 double-strength tablet daily (provides cross-protection against toxoplasmosis and respiratory bacterial infections) 4
  • Alternative: 1 single-strength tablet daily or 1 double-strength tablet three times weekly 4

Post-Transplant Prophylaxis

  • Kidney transplant recipients: Daily TMP-SMX for at least 6 months post-transplant 5

Renal Dose Adjustment

Dosing must be reduced in renal impairment 2, 3:

  • CrCl >30 mL/min: Standard dosing
  • CrCl 15-30 mL/min: 50% of usual dose
  • CrCl <15 mL/min: Use not recommended

Critical Contraindications and Precautions

Absolute Contraindications

  • Infants <2 months of age: Risk of kernicterus 4, 2, 3
  • Third trimester pregnancy: Increased risk of birth defects and kernicterus 1
  • Nursing mothers: Kernicterus risk in infant 1

Monitoring Requirements

  • Hematologic surveillance: Complete blood counts with differential and platelets at initiation and monthly intervals to assess for bone marrow suppression 5
  • Watch for serious reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, interstitial nephritis 1

Antimicrobial Spectrum and Clinical Context

Cotrimoxazole provides broad-spectrum coverage against both Gram-positive and Gram-negative aerobic bacteria, including community-acquired MRSA 1. The combination is effective against Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, and common urinary pathogens 1.

When Cotrimoxazole is Superior to Trimethoprim Alone

The combination is specifically indicated for 6:

  • Pneumocystis jirovecii pneumonia
  • Toxoplasmosis
  • Nocardiosis
  • Brucellosis
  • Chancroid

When Trimethoprim Alone May Suffice

For many common respiratory and urinary tract infections, trimethoprim alone (without sulfamethoxazole) is equally effective with fewer adverse effects 7, 6. However, the fixed-dose combination remains standard in most clinical practice 1, 2, 3.

Common Pitfalls to Avoid

  • Resistance patterns: Increasing bacterial resistance is compromising cotrimoxazole's utility, particularly for empiric treatment of traveler's diarrhea where quinolones are now preferred first-line 4
  • Desensitization option: For patients with non-life-threatening adverse reactions (especially fever and rash), gradual reintroduction with dose escalation allows up to 70% to tolerate the drug 4
  • Avoid empiric use in high-resistance areas: Do not use for UTI prophylaxis when local resistance exceeds 20% 5
  • Consider non-antibiotic alternatives first: For recurrent UTI prevention, try cranberry products, methenamine hippurate, vaginal estrogen, or increased water intake before committing to antibiotic prophylaxis 5

References

Guideline

Bactrim Coverage and Dosing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Daily Prophylactic Dose for Sulfatrim (TMP-SMX) for UTI Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Limitations of and indications for the use of co-trimoxazole.

Journal of chemotherapy (Florence, Italy), 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.